Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy

Description

This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.

Conditions

Pediatric Disorder, Genetic Predisposition, Dystonia, Secondary, Dystonia, Cerebral Palsy, Dystonic-Rigid, Cerebral Palsy, Dyskinetic, Trihexyphenidyl Adverse Reaction, Pharmacogenomic Drug Interaction

Talk to us

Study Overview

On this page

Study Details

Study overview

This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.

Pharmacogenomic Contribution to the Biotransformation of Trihexyphenidyl and Development of a Precision Dosing Model for Children With Dystonia and Cerebral Palsy

Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy

Condition
Pediatric Disorder
Intervention / Treatment

-

Contacts and Locations

Kansas City

Children's Mercy Hospital Kansas City, Kansas City, Missouri, United States, 64108

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Ages 5-17 years of age
  • * Diagnosis of cerebral palsy and dystonia causing interference
  • * Parent/legal guardian of a child with a diagnosis of cerebral palsy and dystonia
  • * Parent/legal guardian is willing and able to provide informed permission/assent for the study
  • * Previously or currently taking trihexyphenidyl
  • * Patients turning 18 years of age within the study period (16 weeks from Study Day 1)
  • * A language barrier for the patient that precludes communication and/or the ability to complete study-related requirements

Ages Eligible for Study

5 Years to 17 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Children's Mercy Hospital Kansas City,

Rose Gelineau-Morel, MD, PRINCIPAL_INVESTIGATOR, Children's Mercy Kansas City

Study Record Dates

2026-10-31